N
Novogene
It is a leading provider of genomic services and solutions with cutting edge NGS
About Novogene
Novogene provides genomic services and solutions, leveraging next-generation sequencing (NGS) and bioinformatics. The company was established in March 2011 in Beijing by Dr. Ruiqiang Li, a recognized expert in genomics and bioinformatics who holds a PhD from the University of Copenhagen. His journey in genomics began in the early 2000s, and he is noted for developing the Short Oligonucleotide Analysis Package (SOAP), a software for sequence mapping and genome assembly. Dr. Li founded Novogene with the aim of offering NGS services complete with bioinformatic analysis to provide researchers with publication-ready data.
The company's business model is centered on providing end-to-end, high-throughput sequencing services as a B2B partner. Its client base includes universities, hospitals, pharmaceutical companies, and agricultural enterprises across more than 70 countries. Revenue is generated by offering a comprehensive suite of services that cover the entire workflow, from DNA/RNA extraction and library preparation to sequencing and data analysis. Novogene operates on a global scale, with laboratories and subsidiaries in the US, UK, Europe, Singapore, and Japan, enabling localized service and support.
Novogene's core offering encompasses a wide array of sequencing services for human, plant, animal, and microbial DNA and RNA. These services include whole genome sequencing, transcriptome sequencing, epigenome sequencing, and metagenome sequencing. The company utilizes advanced sequencing platforms from Illumina, PacBio, and Nanopore to handle large-scale genomic data. A key feature is its self-developed intelligent delivery platform, Falcon, which automates the NGS process to enhance efficiency and quality. Additionally, Novogene offers a cloud-based application, NovoMagic, for data analysis and visualization, and a customer service system for real-time project tracking. A significant milestone was its Initial Public Offering on the Shanghai Stock Exchange's STAR Market on April 13, 2021, ten years after its founding.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Nov 2016 | $71M | $283M | CMB International · China Merchants Bank | — |
Growth signals
Latest recorded traffic for Novogene is 90 monthly website visits, down 98.4% over the last three months. Novogene's team grew 3.1% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Novogene in the Sacramento ecosystem
The Novogene office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
- CICMB International
China Merchants Bank
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Novogene on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Novogene’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









